Table 1. Patient characteristics and endothelial cell outcomes.

UPN	Disease	Donor	Stem cell source	Days posttransplant	GVHD grade	Hematopoietic engraftment	Donor endothelium
1	CML	URD	BM	73	None	Yes	+
2	AML	URD	BM	32	None	Yes	+
3	AML	URD	BM	252	None	Yes	+
4	NHL	Sibling	PBSC	50	None	Yes	+
5	CML	Sibling	PBSC	49	I/II	Yes	+
6	AML	URD	PBSC	9	I/II	Yes	+
7	APL	URD	BM	898	None	Yes	+
8	AML	URD	PBSC	81	I/II	Yes	+
9	CML	Sibling	BM	2,766	None	Yes	+
10	AML	URD	BM	14	None	No	-
11	AML	URD	BM	14	None	No	-
12	AML	Sibling	PBSC	18	None	No	-

Graft-versus-host disease (GVHD) prophylaxis: Patients 2, 3, and 11 received tacrolimus and methotrexate. All others received cyclosporine, methotrexate, and prednisone. Preparative regimens: Patients 2, 3, and 11 received fludarabine, cyclophosphamide, antithymocyte globulin, methylprednisolone, and total body irradiation. Patients 6 and 10 received busulfan/cyclophosphamide. All other patients received cyclophosphamide/total body irradiation. UPN, unique patient number; CML, chronic myeloid leukemia; AML, acute myeloid leukemia; NHL, non-Hodgkin's lymphoma; APL, acute promyelocytic leukemia; URD, unrelated donor; BM, bone marrow.